Conversely, Apatinib’s marked effectiveness in improving PFS may stem from its potent antiangiogenic activity via selective VEGFR-2 inhibition, effectively suppressing neovascularization crucial for HCC growth and metastasis, thereby delaying disease progression more evidently (Zhang et al., 2023). The gene discussed is KDR; the disease is hepatocellular carcinoma.